References
- World Health Organization, World covid19 report, 2021. Available at https://covid19.who.int/.
- J. Zhang, K. Yan, H. Ye, J. Lin, J. Zheng, and T. Cai, SARS-CoV-2 turned positive in a discharged patient with COVID-19 arouses concern regarding the present standards for discharge, Int. J. Infect. Dis. 97 (2020), pp. 212–214. doi:https://doi.org/10.1016/j.ijid.2020.03.007.
- D.S. Hui, E.I. Azhar, T.A. Madani, F. Ntoumi, R. Kock, O. Dar, G. Ippolito, T.D. Mchugh, Z.A. Memish, C. Drosten, A. Zumla, and E. Petersen, The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health — The latest 2019 novel coronavirus outbreak in Wuhan, China, Int. J. Infect. Dis. 91 (2020), pp. 264–266. doi:https://doi.org/10.1016/j.ijid.2020.01.009.
- G. Tan, X. Lian, Z. Zhu, Z. Wang, F. Huang, Y. Zhang, Y. Zhao, S. He, X. Wang, H. Shen, and G. Lyu, Use of lung ultrasound to differentiate coronavirus disease 2019 (COVID-19) pneumonia from community-acquired pneumonia, Ultrasound Med. Biol. 46 (2020), pp. 2651–2658. doi:https://doi.org/10.1016/j.ultrasmedbio.2020.05.006.
- S. Mongodi, A. Orlando, E. Arisi, G. Tavazzi, E. Santangelo, L. Caneva, M. Pozzi, E. Pariani, G. Bettini, G. Maggio, S. Perlini, L. Preda, G.A. Iotti, and F. Mojoli, Lung ultrasound in patients with acute respiratory failure reduces conventional imaging and health care provider exposure to COVID-19, Ultrasound Med. Biol. 46 (2020), pp. 2090–2093. doi:https://doi.org/10.1016/j.ultrasmedbio.2020.04.033.
- L. Yang, Z. Wu, X. Ren, F. Yang, G. He, J. Zhang, J. Dong, L. Sun, Y. Zhu, J. Du, S. Zhang, and Q. Jin, Novel SARS-like betacoronaviruses in bats, China, 2011, Emerg. Infect. Dis. 19 (2013), pp. 989–991. doi:https://doi.org/10.3201/eid1906.121648.
- B. Hu, X. Ge, L.-F. Wang, and Z. Shi, Bat origin of human coronaviruses, Virol. J. 12 (2015), pp. 1–10. doi:https://doi.org/10.1186/s12985-015-0422-1.
- J. Chui, F. Li, and Z.L. Shi, Origin and evolution of pathogenic coronaviruses, Nat. Rev. Microbiol. 17 (2019), pp. 181–192. doi:https://doi.org/10.1038/s41579-018-0118-9.
- S.K.P. Lau, K.S.M. Li, Y. Huang, C.-T. Shek, H. Tse, M. Wang, G.K.Y. Choi, H. Xu, C.S.F. Lam, R. Guo, K.H. Chan, B.J. Zheng, P.C.Y. Woo, and K.Y. Yuen, Ecoepidemiology and complete genome comparison of different strains of severe acute respiratory syndrome-related Rhinolophus bat coronavirus in China reveal bats as a reservoir for acute, self-limiting infection that allows recombination events, J. Virol. 84 (2010), pp. 2808–2819. doi:https://doi.org/10.1128/JVI.02219-09.
- F. Pereira, Evolutionary dynamics of the SARS-CoV-2 ORF8 accessory gene, Infect. Genet. Evol. 85 (2020), pp. 104525. doi:https://doi.org/10.1016/j.meegid.2020.104525.
- X. Zhang, H. Cai, J. Hu, J. Lian, J. Gu, S. Zhang, C. Ye, Y. Lu, C. Jin, G. Yu, H. Jia, Y. Zhang, J. Sheng, L. Li, and Y. Yang, Epidemiological, clinical characteristics of cases of SARS-CoV-2 infection with abnormal imaging findings, Int. J. Infect. Dis. 94 (2020), pp. 81–87. doi:https://doi.org/10.1016/j.ijid.2020.03.040.
- A. Abbad, R.A.P.M. Perera, L. Anga, A. Faouzi, N.N.T. Minh, S.M.M.R. Malik, N. Iounes, A. Maaroufi, M.D. van Kerkhove, M. Peiris, and J. Nourlil, Middle East respiratory syndrome coronavirus (MERS-CoV) neutralising antibodies in a high-risk human population, Morocco, November 2017 to January 2018, Euro Surveill. 24 (2019), pp. 1–8. doi:https://doi.org/10.2807/1560-7917.ES.2019.24.48.1900244.
- H.Z. Farooq, E. Davies, S. Ahmad, N. Machin, L. Hesketh, M. Guiver, and A.J. Turner, Middle East respiratory syndrome coronavirus (MERS-CoV) — Surveillance and testing in North England from 2012 to 2019, Int. J. Infect. Dis. 93 (2020), pp. 237–244. doi:https://doi.org/10.1016/j.ijid.2020.01.043.
- A. Al-Hazmi, Challenges presented by MERS corona virus, and SARS corona virus to global health, Saud. J. Biol. Sci. 23 (2016), pp. 507–511. doi:https://doi.org/10.1016/j.sjbs.2016.02.019.
- J. Lan, J. Ge, J. Yu, S. Shan, H. Zhou, S. Fan, Q. Zhang, X. Shi, Q. Wang, L. Zhang, and X. Wang, Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor, Nature 581 (2020), pp. 215–220. doi:https://doi.org/10.1038/s41586-020-2180-5.
- C.W. Lu, X.F. Liu, and Z.F. Jia, 2019-nCoV transmission through the ocular surface must not be ignored, Lancet 395 (2020), pp. 39. doi:https://doi.org/10.1016/S0140-6736(20)30313-5.
- X. Peng, X. Xu, Y. Li, L. Cheng, X. Zhou, and B. Ren, Transmission routes of 2019-nCoV and controls in dental practice, Int. J. Oral. Sci. 12 (2020), pp. 1–6. doi:https://doi.org/10.1038/s41368-020-0075-9.
- V. Stadnytskyi, C.E. Bax, A. Bax, and P. Anfinrud, The airborne lifetime of small speech droplets and their potential importance in SARS-CoV-2 transmission, Proc. Natl. Acad. Sci. U.S.A. 117 (2020), pp. 11875–11877. doi:https://doi.org/10.1073/pnas.2006874117.
- P. Bahl, C. Doolan, C. de Silva, A.A. Chughtai, L. Bourouiba, and C.R. MacIntyre, Airborne or droplet precautions for health workers treating coronavirus disease 2019? J. Infect. Dis. 189 (2020), pp. 1–29.
- Y. Liu, Z. Ning, Y. Chen, M. Guo, Y. Liu, N.K. Gali, L. Sun, Y. Duan, J. Cai, D. Westerdahl, X. Liu, K.F. Ho, H. Kan, Q. Fu, and K. Lan, Aerodynamic characteristics and RNA concentration of SARS-CoV-2 aerosol in Wuhan hospitals during COVID-19 outbreak, Nature 582 (2020), pp. 557–560. doi:https://doi.org/10.1038/s41586-020-2271-3.
- M. Schwarzinger, V. Watson, P. Arwidson, F. Alla, and S. Luchini, COVID-19 vaccine hesitancy in a representative working-age population in France: A survey experiment based on vaccine characteristics, Lancet Pub. Heal. 2667 (2021), pp. 1–12.
- F.P. Polack, S.J. Thomas, N. Kitchin, J. Absalon, A. Gurtman, S. Lockhart, J.L. Perez, G. Pérez Marc, E.D. Moreira, C. Zerbini, R. Bailey, K.A. Swanson, S. Roychoudhury, K. Koury, P. Li, W.V. Kalina, D. Cooper, R.W. Frenck Jr., L.L. Hammitt, Ö. Türeci, H. Nell, A. Schaefer, S. Ünal, D.B. Tresnan, S. Mather, P.R. Dormitzer, U. Şahin, K.U. Jansen, and W.C. Gruber, Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine, N. Engl. J. Med. 383 (2020), pp. 2603–2615. doi:https://doi.org/10.1056/NEJMoa2034577.
- J.H. Kim, F. Marks, and J.D. Clemens, Looking beyond COVID-19 vaccine phase 3 trials, Nat. Med. 27 (2021), pp. 205–211. doi:https://doi.org/10.1038/s41591-021-01230-y.
- W. Markland, T.J. Mcquaid, J. Jain, and A.D. Kwong, Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX- 497: A comparison with ribavirin and demonstration of antiviral additivity with alpha interferon, Antimicrob. Agents Chemother. 44 (2000), pp. 859–866. doi:https://doi.org/10.1128/AAC.44.4.859-866.2000.
- M. Wang, R. Cao, L. Zhang, X. Yang, J. Liu, M. Xu, Z. Shi, Z. Hu, W. Zhong, and G. Xiao, Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell Res. 30 (2020), pp. 269–271. doi:https://doi.org/10.1038/s41422-020-0282-0.
- P.L. Yang, M. Gao, K. Lin, Q. Liu, and V.A. Villareal, Anti-HCV drugs in the pipeline, Curr. Opin. Virol. 1 (2011), pp. 607–616. doi:https://doi.org/10.1016/j.coviro.2011.10.019.
- A.K. Singh, A. Singh, R. Singh, and A. Misra, Remdesivir in COVID-19: A critical review of pharmacology, pre-clinical and clinical studies, Diabetes Metab. Syndr. 14 (2020), pp. 641–648. doi:https://doi.org/10.1016/j.dsx.2020.05.018.
- N. Narayanan and D.T. Nair, Ritonavir may inhibit exoribonuclease activity of nsp14 from the SARS-CoV-2 virus and potentiate the activity of chain terminating drugs, Int. J. Biol. Macromol. 168 (2021), pp. 272–278. doi:https://doi.org/10.1016/j.ijbiomac.2020.12.038.
- C.J. Gordon, E.P. Tchesnokov, E. Woolner, J.K. Perry, J.Y. Feng, D.P. Porter, and M. Götte, Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency, J. Biol. Chem. 295 (2020), pp. 6785–6797. doi:https://doi.org/10.1074/jbc.RA120.013679.
- J. Huang, W. Song, H. Huang, and Q. Sun, Pharmacological therapeutics targeting RNA-dependent RNA polymerase, proteinase and spike protein: From mechanistic studies to clinical trials for COVID-19, J. Clin. Med. 9 (2020), pp. 1131. doi:https://doi.org/10.3390/jcm9041131.
- S. Ullrich and C. Nitsche, The SARS-CoV-2 main protease as drug target, Bioorg. Med. Chem. Lett. 30 (2020), pp. 127377. doi:https://doi.org/10.1016/j.bmcl.2020.127377.
- S. Chakraborty, Evolutionary and structural analysis elucidates mutations on SARS-CoV2 spike protein with altered human ACE2 binding affinity, Biochem. Biophys. Res. Commun. 538 (2021), pp. 97–103. doi:https://doi.org/10.1016/j.bbrc.2021.01.035.
- J. Osipiuk, S.A. Azizi, S. Dvorkin, M. Endres, R. Jedrzejczak, K.A. Jones, S. Kang, R.S. Kathayat, Y. Kim, V.G. Lisnyak, S.L. Maki, V. Nicolaescu, C.A. Taylor, C. Tesar, Y.A. Zhang, Z. Zhou, G. Randall, K. Michalska, S.A. Snyder, B.C. Dickinson, and A. Joachimiak, Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors, Nat. Commun. 12 (2021), pp. 743. doi:https://doi.org/10.1038/s41467-021-21060-3.
- D. Shin, R. Mukherjee, D. Grewe, D. Bojkova, K. Baek, A. Bhattacharya, L. Schulz, M. Widera, A.R. Mehdipour, G. Tascher, P.P. Geurink, A. Wilhelm, G.J. van der Heden van Noort, H. Ovaa, S. Muller, K.P. Knobeloch, K. Rajalingam, B.A. Schulman, J. Cinatl, G. Hummer, S. Ciesek, and I. Dikic, Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity, Nature 587 (2020), pp. 657–662. doi:https://doi.org/10.1038/s41586-020-2601-5.
- W. Rut, Z. Lv, M. Zmudzinski, S. Patchett, D. Nayak, S.J. Snipas, F.E. Oualid, T.T. Huang, M. Bekes, M. Drag, and S.K. Olsen, Activity profiling and crystal structures of inhibitor-bound SARS-CoV-2 papain-like protease: A framework for anti–COVID-19 drug design, Sci. Adv. 6 (2020), pp. 1–12. doi:https://doi.org/10.1126/sciadv.abd4596.
- R. Arya, A. Das, V. Prashar, and M. Kumar, Potential inhibitors against papain-like protease of novel coronavirus (SARS-CoV-2) from FDA approved drugs, preprint (2020), to appear in Cambridge Open Engage. Available at https://chemrxiv.org/engage/chemrxiv/articledetails/60c74880bdbb893898a38f6.
- B.T. Freitas, I.A. Durie, J. Murray, J.E. Longo, H.C. Miller, D. Crich, R.J. Hogan, R.A. Tripp, and S.D. Pegan, Characterization and noncovalent inhibition of the deubiquitinase and deISGylase activity of SARS-CoV-2 papain-like protease, ACS Infect. Dis. 6 (2020), pp. 2099–2109. doi:https://doi.org/10.1021/acsinfecdis.0c00168.
- M.W. Hull and J.S.G. Montaner, Ritonavir-boosted protease inhibitors in HIV therapy, Ann. Med. 43 (2011), pp. 375–388. doi:https://doi.org/10.3109/07853890.2011.572905.
- K. Uzunova, E. Filipova, V. Pavlova, and T. Vekov, Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2, Biomed. Pharmacother. 131 (2020), pp. 110668. doi:https://doi.org/10.1016/j.biopha.2020.110668.
- X. Gao, B. Qin, P. Chen, K. Zhu, P. Hou, J.A. Wojdyla, M. Wang, and S. Cui, Crystal structure of SARS-CoV-2 papain-like protease, Acta Pharm. Sin. B 11 (2021), pp. 237–245. doi:https://doi.org/10.1016/j.apsb.2020.08.014.
- D. Li, J. Luan, and L. Zhang, Molecular docking of potential SARS-CoV-2 papain-like protease inhibitors, Biochem. Biophys. Res. Commun. 538 (2020), pp. 72–79. doi:https://doi.org/10.1016/j.bbrc.2020.11.083.
- J.M. Blaney and J.S. Dixon, A good ligand is hard to find: Automated docking methods, Perspect. Drug. Discov. Des. 1 (1993), pp. 301–319. doi:https://doi.org/10.1007/BF02174531.
- C.A. Baxter, C.W. Murray, B. Waszkowycz, J. Li, R.A. Sykes, R.G.A. Bone, T.D.J. Perkins, and W. Wylie, New approach to molecular docking and its application to virtual screening of chemical databases, J. Chem. Inform. Comput. Sci. 40 (2000), pp. 254–262. doi:https://doi.org/10.1021/ci990440d.
- D.B. Kitchen, H. Decornez, J.R. Furr, and J. Bajorath, Docking and scoring in virtual screening for drug discovery: Methods and applications, Nat. Rev. Drug Discov. 3 (2004), pp. 935–949. doi:https://doi.org/10.1038/nrd1549.
- S.O. Aftab, M.Z. Ghouri, M.U. Masood, Z. Haider, Z. Khan, A. Ahmad, and N. Munawar, Analysis of SARS-CoV-2 RNA-dependent RNA polymerase as a potential therapeutic drug target using a computational approach, J. Transl. Med. 18 (2020), pp. 275. doi:https://doi.org/10.1186/s12967-020-02439-0.
- S. Sarkar, S. Gupta, W. Chakraborty, S. Senapati, and R. Gachhui, Homology modeling, molecular docking and molecular dynamics studies of the catalytic domain of chitin deacetylase from Cryptococcus laurentii strain RY1, Int. J. Biol. Macromol. 104 (2017), pp. 1682–1691. doi:https://doi.org/10.1016/j.ijbiomac.2017.03.057.
- M.A. Azam, S. Jupudi, N. Saha, and R.K. Paul, Combining molecular docking and molecular dynamics studies for modelling Staphylococcus aureus MurD inhibitory activity, SAR QSAR Environ. Res. 30 (2019), pp. 1–20. doi:https://doi.org/10.1080/1062936X.2018.1539034.
- A.A. Elfiky and A.M. Ismail, Molecular docking revealed the binding of nucleotide/side inhibitors to Zika viral polymerase solved structures, SAR QSAR Environ. Res. 29 (2018), pp. 409–418. doi:https://doi.org/10.1080/1062936X.2018.1454981.
- A. Fiser and A. Šali, MODELLER: Generation and refinement of homology-based protein structure models, Meth. Enzymol. 374 (2003), pp. 461–491.
- O. Trott and A.J. Olson, AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading, J. Comput. Chem. 31 (2010), pp. 455–461.
- N.M. O’Boyle, M. Banck, C.A. James, C. Morley, T. Vandermeersch, and G.R. Hutchison, Open Babel: An open chemical toolbox, J. Cheminform. 3 (2011), pp. 33. doi:https://doi.org/10.1186/1758-2946-3-33.
- G. Morris, R. Huey, W. Linkstrom, M. Sanner, R. Belew, D. Goodsell, and A. Olson, AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility, J. Comput. Chem. 30 (2009), pp. 2785–2791. doi:https://doi.org/10.1002/jcc.21256.
- A. Arwansyah, A.R. Arif, G. Syahputra, S. Sukarti, and I. Kurniawan, Theoretical studies of thiazolyl-pyrazoline derivatives as promising drugs against malaria by QSAR modelling combined with molecular docking and molecular dynamics simulation, Mol. Simul. 47 (2021), pp. 988–1001.
- T. Sumaryada, A. Arwansyah, W. Roslia, L. Ambarsari, and A. Kartono, Molecular docking simulation of mangostin derivatives and curcuminoid on maltase- glucoamylase target for searching anti-diabetes drug candidates, Int. Conf. Bioinform. Biomed. Eng. (2016), pp. 1–4.(https://ieeexplore.ieee.org/document/7869832).
- R. Salomon-Ferrer, D.A. Case, and R.C. Walker, An overview of the Amber biomolecular simulation package, Wiley Interdiscip. Rev. Comput. Mol. Sci. 3 (2013), pp. 198–210. doi:https://doi.org/10.1002/wcms.1121.
- W.L. Jorgensen, J. Chandrasekhar, J.D. Madura, R.W. Impey, and M.L. Klein, Comparison of simple potential functions for simulating liquid water, J. Chem. Phys. 79 (1983), pp. 926–935. doi:https://doi.org/10.1063/1.445869.
- J. Wang, R.M. Wolf, J.W. Caldwell, P.A. Kollman, and D.A. Case, Development and testing of a general Amber force field, J. Comput. Chem. 25 (2004), pp. 1157–1174. doi:https://doi.org/10.1002/jcc.20035.
- J.A. Maier, C. Martinez, K. Kasavajhala, L. Wickstrom, K.E. Hauser, and C. Simmerling, ff14SB: Improving the Accuracy of protein side chain and backbone parameters from ff99SB, J. Chem. Theory Comput. 11 (2015), pp. 3696–3713. doi:https://doi.org/10.1021/acs.jctc.5b00255.
- U. Essmann, L. Perera, M.L. Berkowitz, T. Darden, H. Lee, and L.G. Pedersen, A smooth particle mesh Ewald method, J. Chem. Phys. 103 (1995), pp. 8577–8593. doi:https://doi.org/10.1063/1.470117.
- J.-P. Ryckaert, G. Ciccotti, and H.J.C. Berendsen, Numerical integration of the cartesian equations of motion of a system with constraints: Molecular dynamics of n-alkanes, J. Comput. Phys. 23 (1977), pp. 327–341. doi:https://doi.org/10.1016/0021-9991(77)90098-5.
- R.J. Loncharich, B.R. Brooks, and R.W. Pastor, Langevin dynamics of peptides: The frictional dependence of isomerization rates of N-acetylalanyl-N-methylamide, Biopolymers 32 (1992), pp. 523–535. doi:https://doi.org/10.1002/bip.360320508.
- D.R. Roe and T.E. Cheatham, PTRAJ and CPPTRAJ: Software for processing and analysis of molecular dynamics trajectory data, J. Chem. Theory Comput. 9 (2013), pp. 3084–3095. doi:https://doi.org/10.1021/ct400341p.
- B.R. Miller, T.D. Mcgee, J.M. Swails, N. Homeyer, H. Gohlke, and A.E. Roitberg, MMPBSA .py : An efficient program for end-state free energy calculations, J. Chem. Theory Comput. 8 (2012), pp. 3314–3321. doi:https://doi.org/10.1021/ct300418h.
- S. Salentin, S. Schreiber, V.J. Haupt, M.F. Adasme, and M. Schroeder, PLIP: Fully automated protein-ligand interaction profiler, Nucleic Acids Res. 43 (2015), pp. 443–447. doi:https://doi.org/10.1093/nar/gkv315.
- W.L. DeLano, The PyMOL molecular graphics system, Version 2.3, 2020; sofware available at https://pymol.org/.
- A.C. Wallace, R.A. Laskowski, and J.M. Thornton, Ligplot: A program to generate schematic diagrams of protein-ligand interactions, Protein Eng. 8 (1995), pp. 127–134. doi:https://doi.org/10.1093/protein/8.2.127.
- S. Nakagawa, I. Kurniawan, K. Kodama, M.S. Arwansyah, K. Kawaguchi, and H. Nagao, Theoretical study on interaction of cytochrome f and plastocyanin complex by a simple coarse-grained model with molecular crowding effect, Mol. Phys. 116 (2018), pp. 666–677. doi:https://doi.org/10.1080/00268976.2017.1406160.
- K. Kawaguchi, M.S. Arwansyah, T. Kataoka, and H. Nagao, Theoretical study of conformational transition of CDK4 by association of cyclin D3, Mol. Phys. 117 (2019), pp. 2355–2361. doi:https://doi.org/10.1080/00268976.2018.1563725.
- K. Kawaguchi, S. Nakagawa, I. Kurniawan, K. Kodama, M.S. Arwansyah, and H. Nagao, A coarse-grained model of the effective interaction for charged amino acid residues and its application to formation of GCN4-pLI tetramer, Mol. Phys. 116 (2018), pp. 649–657. doi:https://doi.org/10.1080/00268976.2017.1393574.